File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Advances in immunomodulating therapy of HBV infection

TitleAdvances in immunomodulating therapy of HBV infection
Authors
KeywordsImmunomodulating therapy
HBV infection
Issue Date2005
PublisherIvyspring International Publisher. The Journal's web site is located at http://www.medsci.org/
Citation
International Journal of Medical Sciences, 2005, v. 2 n. 1, p. 24-29 How to Cite?
AbstractPatients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrhosis and hepatocellular carcinoma. Interferon-α, lamivudine and adefovir dipivoxil are the three approved treatment for chronic HBV infection and offers the only means of preventing the development of these complications. However, the efficacy of these agents, in terms of loss of Hepatitis B e antigen with or without seroconversion to Hepatitis B e antibody, normalization of serum alanine transaminase levels, loss of serum HBV DNA, and improvement in liver histology can only be achieved in 20-30% of those treated. Long-term treatment with either lamivudine or adefovir dipivoxil can result in the development of drug resistant mutants leading to an increased length of treatment with additional nucleoside analogues. These limitations of the current antiviral therapies underline the need for alternative therapies. Specific and nonspecific immunotherapeutic strategies to restore effective virus-specific T cell responses in those with chronic HBV infection offers an interesting alternative approach. These immunotherapeutic therapies include the adoptive transfer of HBV immunity, pegylated interferon and therapeutic vaccine therapies.
Persistent Identifierhttp://hdl.handle.net/10722/44947
ISSN
2015 Impact Factor: 2.232
2015 SCImago Journal Rankings: 0.813
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_HK
dc.contributor.authorLau, GKKen_HK
dc.date.accessioned2007-10-30T06:14:09Z-
dc.date.available2007-10-30T06:14:09Z-
dc.date.issued2005en_HK
dc.identifier.citationInternational Journal of Medical Sciences, 2005, v. 2 n. 1, p. 24-29en_HK
dc.identifier.issn1449-1907en_HK
dc.identifier.urihttp://hdl.handle.net/10722/44947-
dc.description.abstractPatients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrhosis and hepatocellular carcinoma. Interferon-α, lamivudine and adefovir dipivoxil are the three approved treatment for chronic HBV infection and offers the only means of preventing the development of these complications. However, the efficacy of these agents, in terms of loss of Hepatitis B e antigen with or without seroconversion to Hepatitis B e antibody, normalization of serum alanine transaminase levels, loss of serum HBV DNA, and improvement in liver histology can only be achieved in 20-30% of those treated. Long-term treatment with either lamivudine or adefovir dipivoxil can result in the development of drug resistant mutants leading to an increased length of treatment with additional nucleoside analogues. These limitations of the current antiviral therapies underline the need for alternative therapies. Specific and nonspecific immunotherapeutic strategies to restore effective virus-specific T cell responses in those with chronic HBV infection offers an interesting alternative approach. These immunotherapeutic therapies include the adoptive transfer of HBV immunity, pegylated interferon and therapeutic vaccine therapies.en_HK
dc.format.extent227712 bytes-
dc.format.extent3198304 bytes-
dc.format.extent2221 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherIvyspring International Publisher. The Journal's web site is located at http://www.medsci.org/en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectImmunomodulating therapyen_HK
dc.subjectHBV infectionen_HK
dc.titleAdvances in immunomodulating therapy of HBV infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1449-1907&volume=2&issue=1&spage=24&epage=29&date=2005&atitle=Advances+in+immunomodulating+therapy+of+HBV+infectionen_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid15968336en_HK
dc.identifier.pmcidPMC1142221-
dc.identifier.scopuseid_2-s2.0-21644476001-
dc.identifier.hkuros100545-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats